Clicky

Kymera Therapeutics, Inc.(KYMR)

Description: Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.


Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Disease Rheumatoid Arthritis Atopic Dermatitis Autoimmunity Dermatitis Hematologic Malignancies Hidradenitis Suppurativa Irak4

Home Page: www.kymeratx.com

KYMR Technical Analysis

200 Arsenal Yards Boulevard
Watertown, MA 02472
United States
Phone: 857 285 5300


Officers

Name Title
Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D. Co-Founder & Chairman
Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, Pres, CEO & Director
Mr. Bruce N. Jacobs CFA Chief Financial Officer
Dr. Jared A. Gollob M.D. Chief Medical Officer
Ms. Elaine Caughey Chief Bus. Officer
Kevin Dushney Sr. VP of IT & Operations
Mr. Michael J. Todisco VP of Accounting & Fin.
Mr. Vijay Sabesan Sr. VP of Technical Operations
Ms. Melissa Brody VP of Bus. Devel.
Ms. Karen Weisbach VP of People & Culture

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.1685
Price-to-Sales TTM: 33.3041
IPO Date: 2020-08-21
Fiscal Year End: December
Full Time Employees: 169
Back to stocks